Skip Navigation


Human Molecular Genetics Advance Access originally published online on January 6, 2004
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
13/4/437    most recent
ddh045v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Piccioni, F.
Right arrow Articles by Taylor, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Piccioni, F.
Right arrow Articles by Taylor, J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2004, Vol. 13, No. 4 437-446
DOI: 10.1093/hmg/ddh045

A screen for drugs that protect against the cytotoxicity of polyglutamine-expanded androgen receptor

Federica Piccioni1, Benjamin R. Roman1, Kenneth H. Fischbeck1 and J. Paul Taylor1,2,*

1Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-1250, USA and 2University of Pennsylvania School of Medicine, Department of Neurology, Philadelphia, PA 19104, USA

Received October 21, 2003; Accepted December 17, 2003

Spinobulbar muscular atrophy is a neurodegenerative disorder caused by expansion of a CAG triplet repeat sequence encoding a polyglutamine tract in the androgen receptor. It has been shown that the mutant protein is toxic in cell culture and triggers an apoptotic cascade resulting in activation of caspase-3. We developed an assay of caspase-3 activation in cells expressing the mutant androgen receptor. This assay was used to screen 1040 drugs, most of which are approved for clinical use. Drugs that inhibit polyglutamine-dependent activation of caspase-3 were subjected to follow-up screens to identify compounds that reproducibly prevent polyglutamine-induced cytotoxicity. Four drugs satisfied these criteria. Three of these (digitoxin, nerifolin and peruvoside) are structurally and functionally related compounds of the cardiac glycoside class and known inhibitors of Na+K+-ATPase. The fourth compound, suloctidil, is a calcium channel blocker.

* To whom correspondence should be addressed at: Department of Neurology, University of Pennsylvania School of Medicine, 3 West Gates Building, 3400 Spruce St, Philadelphia, PA 19104, USA. Tel: +1 2155731147; Fax: +1 2155731153; Email: jpt{at}mail.med.upenn.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
Y. Bian, A. Masuda, T. Matsuura, M. Ito, K. Okushin, A. G. Engel, and K. Ohno
Tannic acid facilitates expression of the polypyrimidine tract binding protein and alleviates deleterious inclusion of CHRNA1 exon P3A due to an hnRNP H-disrupting mutation in congenital myasthenic syndrome
Hum. Mol. Genet., April 1, 2009; 18(7): 1229 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
S. Ranganathan, G. G. Harmison, K. Meyertholen, M. Pennuto, B. G. Burnett, and K. H. Fischbeck
Mitochondrial abnormalities in spinal and bulbar muscular atrophy
Hum. Mol. Genet., January 1, 2009; 18(1): 27 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
I. Palazzolo, B. G. Burnett, J. E. Young, P. L. Brenne, A. R. La Spada, K. H. Fischbeck, B. W. Howell, and M. Pennuto
Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity
Hum. Mol. Genet., July 1, 2007; 16(13): 1593 - 1603.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
L. Wang, B. A. Wible, X. Wan, and E. Ficker
Cardiac Glycosides as Novel Inhibitors of Human Ether-a-go-go-Related Gene Channel Trafficking
J. Pharmacol. Exp. Ther., February 1, 2007; 320(2): 525 - 534.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. K. T. Wang, S. Portbury, M. B. Thomas, S. Barney, D. J. Ricca, D. L. Morris, D. S. Warner, and D. C. Lo
Cardiac glycosides provide neuroprotection against ischemic stroke: Discovery by a brain slice-based compound screening platform
PNAS, July 5, 2006; 103(27): 10461 - 10466.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
U. A. Desai, J. Pallos, A. A. K. Ma, B. R. Stockwell, L. M. Thompson, J. L. Marsh, and M. I. Diamond
Biologically active molecules that reduce polyglutamine aggregation and toxicity
Hum. Mol. Genet., July 1, 2006; 15(13): 2114 - 2124.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. M. Langenhan, N. R. Peters, I. A. Guzei, F. M. Hoffmann, and J. S. Thorson
Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization
PNAS, August 30, 2005; 102(35): 12305 - 12310.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.